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http://dx.doi.org/10.1016/j.jmii.2013Background: The optimal combination ratio of imipenem to colistin methanesulfonate (CMS)
against imipenem-nonsusceptible multidrug-resistant Acinetobacter baumannii (INS-MDRAB)
has not been determined in previous studies. To provide an alternative therapeutic option
for clinical INS-MDRAB isolates, we investigated whether clinically achievable serum concen-
trations of CMS in combination with imipenem enhance the in vitro activity of imipenem
against the INS-MDRAB isolates.
Materials and methods: Fifty-nine INS-MDRAB isolates with imipenem minimal inhibitory con-
centration (MIC) values of 8 mg/L were selected randomly from the Clinical Microbiology Lab-
oratory at a university-affiliated medical center between July 1998 and May 2005. The in vitro
activity of imipenem among these 59 clinical isolates was explored via serial two-fold dilutions
containing a range of imipenem concentration from 0.125 mg/L to 256 mg/L, in combination
with two fixed CMS concentrations at 0.5 mg/L and 1 mg/L. Genotype classification was per-
formed using the pulsed-field gel electrophoresis method and infrequent-restriction-site poly-
merase chain reaction.nfectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, 5 Fu-
aiwan.
org.tw (H.-S. Leu).
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Imipenem/CMS combination against A. baumannii 407Results: A significant reversal of imipenem resistance (i.e., MICs  4 mg/L) was observed in 34
(57.6%) isolates and 44 (74.6%) isolates with the tests of CMS concentrations at 0.5 mg/L and
1 mg/L, respectively (p Z 0.041). Genotype 1 was predominant (43 isolates, 72.9%) with imi-
penem resistance reversal rates of 51.2% and 79.1% (pZ 0.004) in the tests of CMS at 0.5 mg/L
and 1 mg/L, respectively.
Conclusion: The synergy of imipenem/CMS against INS-MDRAB was significantly better for the
CMS concentration at 1 mg/L than that at 0.5 mg/L, especially in our predominant clone. Our
results provided insightful information for treating INS-MDRAB infections in clinical practice.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Multidrug-resistant Acinetobacter baumannii (MDRAB) is
often defined as A. baumannii resistant to three or more of
the following classes of antimicrobials: aminoglycosides,
antipseudomonal fluoroquinolones, antipseudomonal car-
bapenems, extended-spectrum cephalosporins, anti-
pseudomonal penicillins plus beta-lactamase inhibitors,
sulbactam, polymyxins, and tigecycline.1,2 Carbapenem-
nonsusceptible A. baumannii has emerged as an impor-
tant nosocomial pathogen in the hospital setting. Most of
them were MDRAB with resistance to multiple antibiotics
and in vitro susceptibility to only a few drugs, such as
colistin.3,4 Colistin methanesulfonate (CMS), a parenteral
formulation of colistin, was gradually abandoned by clini-
cians in the 1960s and 1970s due to frequently reported
dose-dependent side effects, such as nephrotoxicity and
neurotoxicity. In recent years, CMS has been reintroduced
in clinical practice due to limited therapeutic options for
carbapenem-nonsusceptible MDRAB.4
Either in vivo or in vitro, CMS is readily hydrolyzed to
colistin, which was considered an active form of the drug
with a concentration-dependent bactericidal effect against
Acinetobacter species.4,5 However, in recent pharmacoki-
netic studies, the achieved plasma colistin concentrations
were found to be in the range of only 1e4 mg/L after
intravenous administration of CMS in humans,6e8 which
suggested that the currently recommended CMS dosage
might be suboptimal for antibacterial effect in treating
pathogens with higher minimal inhibitory concentrations
(MICs).4,5,8 Dose escalation may maximize CMS efficacy
against MDRAB but, at the same time, may increase dose-
dependent toxicities.4
Imipenem/CMS combination can be an alternative ther-
apeutic option for infections due to imipenem-
nonsusceptible MDRAB (INS-MDRAB),9,10 and a high serum
level of colistin to achieve the concentration-dependent
bactericidal effect may not be necessary under such a
combination. Imipenem/CMS combination can improve the
activity of imipenem against INS-MDRAB via a synergistic or
additive effect with a lower serum level of colistin, reduce
the dose-dependent toxicities, and prevent the emergence
of colistin heteroresistance during colistin mono-
therapy.9e11 In clinical practice, it is difficult to provide the
optimal combination ratio of imipenem to CMS for individ-
ual cases, according to previous synergy study.3 To provide
an alternative therapeutic option for clinical INS-MDRAB
isolates, we conducted a study to examine the in vitro
activity of imipenem in combination with CMS at fixedconcentrations of 0.5 mg/L and 1 mg/L, which were
achievable serum CMS or colistin concentrations in prior
studies.6e8 The aim of this study was to investigate the
imipenem resistance reversal in clinical INS-MDRAB isolates
using imipenem in combination with CMS at clinically
achievable concentrations.Materials and methods
Bacterial isolates and genotype classification
The Chang Gung Memorial Hospital at Linkou is a 3715-bed
university-affiliated medical center with 308 intensive-care-
unit beds in northern Taiwan. A central microbiology labo-
ratory is responsible for processing all clinical specimens.
For the surveillance of hospital epidemiology, A. baumannii
clinical isolates were collected in the first week of each
month between July 1998 and May 2005, and were stored in
skimmed milk at e70C in the central microbiology labora-
tory. A total of 2475 A. baumannii isolates were stored
during this period. A. baumannii was identified by the
Gram’s stain and conventional biochemical tests.12 Briefly,
the identification of clinical isolates as the genus Acineto-
bacter is based on the following properties: aerobic, Gram-
negative, nonmotile coccobacillary rods with a non-
fermentative, catalase-positive, and oxidase-negative re-
action. Acinetobacter species with glucose-oxidizing
nonhemolytic characteristics are classified as A. baumannii.
The antibiotic disks (Becton Dickinson Microbiology Sys-
tems, Cockeysville, MD, USA) for the susceptibility testing
of A. baumannii included gentamicin, amikacin, ceftazi-
dime, cefepime, aztreonam, ciprofloxacin, piperacillin,
and imipenem. The disk diffusion susceptibility to all tested
antibiotics was based on the Clinical and Laboratory Stan-
dards Institute (CLSI) criteria.13 Of the 2475 stored A.
baumannii isolates, 1196 were MDRAB isolates with a vari-
able susceptibility to imipenem but resistance to all the
other classes of antibiotics mentioned above.2 Among the
1196 MDRAB isolates (including imipenem-susceptible and
imipenem-nonsusceptible strains) 90 were selected
randomly and 59 of them were INS-MDRAB, all of which
were included in this study.
Genotype classification was performed for these 59 iso-
lates using the pulsed-field gel electrophoresis (PFGE)
method and infrequent-restriction-site polymerase chain
reaction (IRS-PCR) that had been used in previous
studies.14,15 Band patterns were analyzed comparatively,
according to the criteria of Tenover et al.14
Table 1 Results of the synergy study for imipenem/CMS
combination against the six randomly selected INS-MDRAB
isolates
Isolate code Genotype FICI value Interpretation
615 Non-1 0.563 Indifference
622 Non-1 0.375 Synergy
623 Non-1 0.5 Synergy
1456 1 0.25 Synergy
1468 1 0.25 Synergy
1523 1 0.266 Synergy
CMS Z colistin methanesulfonate; FICI Z fractional inhibitory
concentration index; INS-MDRAB Z imipenem-nonsusceptible
multidrug-resistant Acinetobacter baumannii.
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antimicrobial agents
Standard powders of imipenem and CMS were obtained
from Merck (Rahway, NJ, USA) and Sigma-Aldrich (St. Louis,
MO, USA), respectively. The MICs of imipenem and CMS for
the 59 INS-MDRAB isolates were determined by the broth
microdilution method, according to the CLSI criteria.13 The
MIC value for imipenem nonsusceptibility was 8 mg/L.13
The synergy study for IPM/CMS combinations was per-
formed for six isolates selected randomly from the 59 INS-
MDRAB isolates, using the checkerboard method.16 Serial
two-fold dilutions for imipenem (ranging from 0.125 mg/L
to 256 mg/L) and CMS (ranging from 0.125 mg/L to 8 mg/L)
were mixed in the cation-supplemented Mu¨ellereHinton
broth (Oxoid Ltd., Hampshire, England). Each well con-
tained 0.1 mL of individual antimicrobial combinations or
broth controls. The final bacterial concentration after
inoculation was 5  105 colony-forming units/mL (CFU/mL).
After 24 hours of incubation at 35C, the MIC was deter-
mined to be the minimal concentration at which there was
no visible growth. Quality control was performed in each
experiment using reference strains, Escherichia coli ATCC
25922 and Pseudomonas aeruginosa ATCC 27853.13 The
synergistic effects of the combination of two antimicrobials
were based on a calculation of the fractional inhibitory
concentration index (FICI) for each drug pair. The fractional
inhibitory concentration (FIC) of each antimicrobial agent
was calculated using the following equations: FIC of
imipenem Z MIC of imipenem in combination/MIC of imi-
penem alone, and the FIC of CMS Z MIC of CMS in combi-
nation/MIC of CMS alone. FICI is the summation of FIC
values for the drugs in combination.16 FICI results for each
combination were interpreted as follows: synergistic,
FICI  0.5; partially synergistic, 0.5 < FICI < 1; additive,
FICI Z 1; indifferent, 1 < FICI < 4; and antagonistic,
FICI  4.16 In vitro susceptibility change of imipenem in
combination with CMS against all 59 INS-MDRAB isolates was
investigated with serial two-fold dilutions for imipenem
ranging from 0.125 mg/L to 256 mg/L and CMS at fixed
concentrations of 0.5 mg/L and 1 mg/L.
Statistical methods
All statistical analyses were performed using the SPSS for
Windows (version 15.0; SPSS Inc., Chicago, IL, USA). Cate-
gorical variables were compared using the c2 test or Fisher
exact test, as appropriate. Paired samples were compared
using the McNemar’s test. All tests were two tailed, and
p <0.05 was considered significant.
Results
The results of the synergy study for IPM/CMS combinations
against six randomly selected INS-MDRAB isolates are shown
in Table 1. Among these six isolates, five had synergistic
effects with FICI values ranging from 0.25 to 0.5 and one
had indifferent effect with a FICI value of 0.563. The
changes of imipenem MICs of the 59 isolates tested with
imipenem in combination with CMS at fixed concentrations
of 0.5 mg/L and 1 mg/L are shown, respectively, in Tables 2and 3. In the test with CMS concentration at 0.5 mg/L, the
MIC50 and MIC90 values of imipenem alone were 8 mg/L and
16 mg/L, respectively (Table 2). Among the 59 isolates
tested with imipenem/CMS combination, 18 (30.5%) had at
least a four-fold decrease in imipenem MICs and 34 (57.6%)
had a reversal of imipenem resistance with the change of
imipenem MICs from 8 to 4 mg/L (Table 2). In the test
with CMS at concentration at 1 mg/L, the MIC50 and MIC90
values of imipenem alone were 16 mg/L and 32 mg/L,
respectively (Table 3). Among the 59 isolates tested with
the combinations, 34 (57.6%) had at least a four-fold
decrease in imipenem MICs and 44 (74.6%) had imipenem
MICs  4 mg/L (Table 3). Most isolates with reversal of
imipenem resistance had at least a four-fold decrease in
MICs (33/44, 75%; Table 3). The imipenem/CMS combina-
tion with the CMS concentration of 1 mg/L had a higher
reversal rate of imipenem resistance than that with the CMS
concentration of 0.5 mg/L (74.6% vs. 57.6%, p Z 0.041;
Table 4).
Twenty-two INS-MDRAB isolates with the CMS MIC of
1 mg/L were tested with imipenem in combination with
CMS at concentrations of 0.5 mg/L and 1 mg/L, and the
reversal rates of imipenem resistance were 63.6% and
81.8%, respectively (p Z 0.219). Of 37 isolates with CMS
MICs  2 mg/L, 34 had a MIC of 2 mg/L, and the MICs of the
remaining three were 4 mg/L, 8 mg/L, and >8 mg/L,
respectively. Among these 37 isolates, the reversal rates of
imipenem resistance tested with imipenem in combination
with CMS at concentrations of 0.5 mg/L and 1 mg/L were
54.1% and 70.3%, respectively (p Z 0.180; Table 4).
The genetic associations of the 59 A. baumannii isolates
determined by the PFGE method and IRS-PCR were sepa-
rated into 12 distinct groups. Genotype 1 was the pre-
dominant genotype (43/59, 72.9%). The imipenem
susceptibility in the test of imipenem combined with
various concentrations of CMS in different genotypes is
shown in Table 5. A comparison between the genotype 1
isolates and others showed that the genotype 1 had a lower
rate of imipenem resistance reversal when tested with a
CMS concentration of 0.5 mg/L (51.2% vs. 75.0%, pZ 0.100)
but a higher rate of imipenem resistance reversal when
tested with a CMS concentration of 1 mg/L (79.1% vs. 62.5%,
p Z 0.312). Compared with the genotype 1 isolates tested
with a CMS concentration of 0.5 mg/L, there was a 27.9%
increase in the imipenem resistance reversal rate when the
Table 2 Imipenem MICs of the 59 INS-MDRAB isolates tested with imipenem alone and the imipenem MIC change of the 59
isolates tested with imipenem in combination with CMS at a fixed concentration of 0.5 mg/La
IPM MIC
(mg/L)
Isolatesb
(n Z 59)
IPM MIC change in combination with CMSc
No change 1/2 1/4 1/8 1/64
256 1 (1.7) 1
32 3 (5.1) 3
MIC90 16 19 (32.2) 4 5 6 3 1
MIC50 8 36 (61.0) 12 19 4 1
a Gray area presents the number of INS-MDRAB isolates with IPM MICs  4 mg/L in IPM/CMS combination.
b Data are presented as n (%).
c Data are presented as n.
CMS Z colistin methanesulfonate; INS-MDRAB Z imipenem-nonsusceptible multidrug-resistant Acinetobacter baumannii;
IPM Z imipenem; MIC Z minimal inhibitory concentration.
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difference was statistically significant (79.1% vs. 51.2%,
p Z 0.004). However, such difference in the isolates of
genotype non-1 was not statistically significant (75.0% vs.
62.5%, p Z 0.625; Table 5).Discussion
In this study, the imipenem/CMS combination improved the
in vitro activity of imipenem for most of the studied INS-
MDRAB isolates. The imipenem MIC 4 mg/L was thought
to be in vitro susceptible. The decrease of imipenem MICs
to 4 mg/L was noted in most cases, and the synergy of the
combination with CMS at 1 mg/L had a better effect than
that at 0.5 mg/L, especially in the isolates of genotype 1,
which was the predominate genotype in our isolates. The
rationale of the combination therapy in A. baumannii in-
fections is to reduce the emergence of resistant isolates
and strengthen the efficacy of treatment itself. However,
there are no well-designed clinical trials comparing treat-
ment regimens for MDRAB infections. This study provided
an alternative therapeutic strategy in treating INS-MDRAB
infections: imipenem combined with CMS at a fixed con-
centration of 1 mg/L, may achieve a reversal of imipenem
resistance in up to 74.6% of these MDRAB isolates initially
with full or intermediate imipenem resistance.Table 3 Imipenem MICs of the 59 INS-MDRAB isolates tested w
isolates tested with imipenem in combination with CMS at a fixed
IPM MIC
(mg/L)
Isolatesb
(n Z 59)
IPM
No change 1/2
256 1 (1.7) 1
64 2 (3.4)
MIC90 32 4 (6.8)
MIC50 16 28 (47.5) 3 7
8 24 (40.7) 3 11
a Gray area presents the number of INS-MDRAB isolates with IPM MI
b Data are presented as n (%).
c Data are presented as n.
CMS Z colistin methanesulfonate; INS-MDRAB Z imipenem-n
IPM Z imipenem; MIC Z minimal inhibitory concentration.The aim of our study is to provide a feasible alternative
therapeutic regimen, based on the data from the investi-
gation of a tertiary teaching hospital, but our results may
not be applicable to all hospital settings due to variations in
hospital epidemiology and antibiotic resistance patterns.
Our isolates were collected from a single institution, and
genotype classification was performed by the PFGE method
and IRS-PCR. It showed that one predominant clone existed
in our institution, which had a significant decrease in imi-
penem MICs while tested with imipenem/CMS combina-
tions. The PFGE method and IRS-PCR have been used in
epidemiologic studies of numerous A. baumannii outbreaks
and are currently regarded as the gold standards for
epidemiologic typing.15,17 However, its poor interlaboratory
reproducibility may limit its role in the comparison of re-
sults between different laboratories. Multilocus sequence
typing is a more discriminative method of typing A. bau-
mannii for interlaboratory comparisons.18
We cannot determine which of colistin or CMS improved
the in vitro effect of imipenem. The response of imipenem
resistance reversal in this study may even be under-
estimated. The reasons are as follows. First, the real con-
centrations of CMS or colistin would be 0.5 mg/L or 1 mg/
L during the testing with CMS hydrolysis, and the response
in this study was achieved with a lower concentration of
CMS or colistin than the concentration we reported. Sec-
ond, the response of imipenem resistance reversal wasith imipenem alone and the imipenem MIC change of the 59
concentration of 1 mg/La
MIC change in combination with CMSc
1/4 1/8 1/16 1/32 1/128
2
1 2 1
8 8 1 1
7 2 1
Cs  4 mg/L in IPM/CMS combination.
onsusceptible multidrug-resistant Acinetobacter baumannii;
Table 4 Change of imipenem susceptibility in the 59 INS-MDRAB isolates tested with imipenem alone and in combination with
CMS at various concentrations
Tested antibiotics Isolates with IPM susceptibility (IPM MIC  4 mg/La)
CMS MIC Z 1 mg/L
(n Z 22)
CMS MIC2 mg/L
(n Z 37)
Total
(n Z 59)
IPM alone 0 (0%) 0 (0%) 0 (0%)
IPM þ CMS (0.5 mg/L) 14 (63.6%) 20 (54.1%) 34 (57.6%)
IPM þ CMS (1 mg/L) 18 (81.8%) 26 (70.3%) 44 (74.6%)
a Data are presented as n (%).
CMS Z colistin methanesulfonate; INS-MDRAB Z imipenem-nonsusceptible multidrug-resistant Acinetobacter baumannii;
IPM Z imipenem; MIC Z minimal inhibitory concentration.
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concentrations, the higher the rates of imipenem resis-
tance reversal. Applying our data in clinical practice does
not necessarily depend on the increasing doses of CMS to
achieve the concentration-dependent bacterial effect.
Most of our INS-MDRAB isolates had high CMS MICs, and the
serum concentrations with bactericidal effect might be
unachievable from current CMS dose regimens. This study
provided a strategy to improve imipenem activity against
INS-MDRAB isolates with achievable serum concentrations
of colistin or CMS demonstrated in previous studies.6e8
In this study, the tests with CMS at concentrations of
0.5 mg/L and 1 mg/L were performed at different times for
the 59 clinical INS-MDRAB isolates, and discordant results
were reported for imipenem MICs while testing with imi-
penem alone for each isolate in the two tests. All the var-
iations conformed to the accepted norm of MIC testing
(mode  1 dilution), and no isolates were tested as
imipenem-susceptible strains (i.e., imipenem MIC 4 mg/L)
in the absence of CMS combination. Compared with the CMS
concentration of 0.5 mg/L in the combination, CMS con-
centration of 1 mg/L achieved a higher rate of at least a
four-fold decrease in imipenem MICs (75.0%) among the
isolates with imipenem resistance reversal, under higher
levels of MIC50 and MIC90. This study showed a significant
difference in the imipenem susceptibility of the INS-MDRAB
isolates between the use of imipenem alone and the imi-
penem/CMS combination; however, the possibilities for
reproducibility errors in an MIC checkerboard could not be
completely excluded.Table 5 Imipenem susceptibility in different genotypes of
INS-MDRAB isolates tested with imipenem in combination
with CMS at various concentrations
Tested antibiotics Isolates with IPM susceptibility
(IPM MIC 4 mg/L)a
Genotype 1
(n Z 43)
Genotype non-1
(n Z 16)
IPM þ CMS (0.5 mg/L) 22 (51.2) 12 (75.0)
IPM þ CMS (1 mg/L) 34 (79.1) 10 (62.5)
a Data are presented as n (%).
CMS Z colistin methanesulfonate; INS-MDRAB Z imipenem-
nonsusceptible multidrug-resistant Acinetobacter baumannii;
IPM Z imipenem; MIC Z minimal inhibitory concentration.In conclusion, the combination ratio of imipenem to CMS
in this study reversed full or intermediate imipenem resis-
tance in most of the INS-MDRAB isolates in vitro, and the
CMS concentration of 1 mg/L had a significantly better ef-
fect than that of 0.5 mg/L, especially in our predominant
clone. The results provided insightful information for clin-
ical practice in treating INS-MDRAB infections in our insti-
tution. Our study was limited to the in vitro antibacterial
combination testing; therefore, this combination needs to
be interpreted in further clinical studies to delineate its
clinical response.Conflicts of interest
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